DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 03/01/2019 --House Dust Mite Allergy (HDMA) - Market and Epidemiology Report

Approximately 1% to 2% of the world's population might be affected with House Dust Mite Allergy, which is equivalent to 65 to 130 million persons in 2018.

1. The prevalence of HDM allergy is intricately linked to exposure to the mite itself.
2. More than 50% of Europeans will suffer from allergic rhinitis in the coming 10 years.
3. In Europe, HDM allergic sensitization is above 20%; it is rising up to 40% in some cohorts in North America.

DelveInsight launched House Dust Mite Allergy (HDMA) - Market Insights, Epidemiology and Market Forecast- 2028

Key topics covered

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the House Dust Mite Allergy market
2. Organize sales and marketing efforts by identifying the best opportunities for House Dust Mite Allergy market
3. To understand the future market competition in the House Dust Mite Allergy market.

"Among patients from 15 developed countries in the European Community Respiratory Health Survey I, the mean prevalence of sensitization to HDM was 21.7%."

Request for sample pages

Currently, the therapeutic market for House Dust Mite Allergy (HDMA) is majorly dominated by Antihistamines (fexofenadine, loratadine); Nasal corticosteroids (beclometasone), Leukotriene receptor antagonists (montelukast, zafirlukast), Cromolyn sodium and Decongestants (oxymetazoline, phenylephrine, naphazoline). However, many people do not get complete relief from these medicines. Therefore, they are required to take immunotherapy (Allergy-shots). Based on the route of administration, two types of allergy shots are available. These are Subcutaneous Immunotherapy (SCIT) and Sublingual (under-the-tongue) immunotherapy (SLIT). These shots are effective in treating reactions to many allergens including trees, grass, weeds, mold, house dust, dander, and insect stings.

The market size of House Dust Mite Allergy is believed to experience a positive growth during the forecast period due to the increasing prevalence, the rise in the incidence of allergic disorders and expected launch of novel therapies [2018-2027]. The competitive landscape of House Dust Mite Allergy is set to change due to the advent of targeted immunotherapies like SCIT and SLIT.

House Dust Mite Allergy companies covered
1. Stallergenes Greer
2. ALK-Abello
3. ASIT Biotech
4. HAL Allergy Group
5. Circassia Limited
6. Allergopharma
And many others

House Dust Mite Allergy Drugs covered
1. SLIT tablets of HDM allergen extracts
2. ToleroMune
3. SUBLIVAC FIX Mite mixture
4. MM09
And many others

Table of contents
1. Key Insights
2. House Dust Mite Allergy Market Overview at a Glance
3. House Dust Mite Allergy: Disease Background and Overview
4. Epidemiology and Patient Population
5. 7MM Total Prevalence of HDM Induced Respiratory Allergy
6. Country Wise-Epidemiology of House Dust Mite Allergy
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
6.9. Treatment Algorithm
7. Unmet Needs
8. Marketed Drug Analysis
8.1. Odactra: Merck Sharp & Dohme Corp.
8.2. Actair: Shionogi & Co.
9. House Dust Mite Allergy: 7 Major Market Analysis
10. The United States Market Outlook
11. EU-5 Countries: Market Outlook
11.1. Germany
11.2. France
11.3. Italy
11.4. Spain
11.5. United Kingdom
11.6. Japan: Market Outlook
12. Market Drivers
13. Market Barriers
14. Appendix
14.1. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight